Lodge et al.

**Supplementary File 2**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Embryonic** | | **Postnatal** | |
| **Genotype** | **Observed** | **Expected** | **Observed** | **Expected** |
| *Hesx1+/+;Lats1fl/+;Lats2+/+* | 2  (1.6%) | 3-4  (2.75%) | 4  (2.1%) | 5-6  (2.75%) |
| *Hesx1+/+;Lats1fl/+;Lats2fl/+* | 4  (3.3%) | 15-16  (12.5%) | 9  (4.7%) | 23-24  (12.5%) |
| *Hesx1+/+;Lats1fl/+;Lats2fl/fl* | 19  (15.4%) | 11-12  (9.75%) | 32  (16.8%) | 18-19  (9.75%) |
| *Hesx1+/+;Lats1fl/fl;Lats2+/+* | 1  (0.8%) | 3-4  (2.75%) | 3  (1.6%) | 5-6  (2.75%) |
| *Hesx1+/+;Lats1fl/fl;Lats2fl/+* | 10  (8.1%) | 15-16  (12.5%) | 11  (5.8%) | 23-24  (12.5%) |
| *Hesx1+/+;Lats1fl/fl;Lats2fl/fl* | 14  (11.4%) | 11-12  (9.75%) | 44  (23.0%) | 18-19  (9.75%) |
| *Hesx1Cre/+;Lats1fl/+;Lats2+/+* | 9  (7.3%) | 3-4  (2.75%) | 17  (8.9%) | 5-6  (2.75%) |
| *Hesx1Cre/+;Lats1fl/+;Lats2fl/+* | 23  (18.7%) | 15-16  (12.5%) | 30  (15.7%) | 23-24  (12.5%) |
| *Hesx1Cre/+;Lats1fl/+;Lats2fl/fl* | 9  (7.3%) | 11-12  (9.75%) | 7  (3.7%) | 18-19  (9.75%) |
| *Hesx1Cre/+;Lats1fl/fl;Lats2+/+* | 9  (7.3%) | 3-4  (2.75%) | 10  (5.2%) | 5-6  (2.75%) |
| *Hesx1Cre/+;Lats1fl/fl;Lats2fl/+* | 18  (14.6%) | 15-16  (12.5%) | 24  (12.6%) | 23-24  (12.5%) |
| *Hesx1Cre/+;Lats1fl/fl;Lats2fl/fl* | 5  (4.1%) | 11-12  (9.75%) | 0  (0%) | 18-19  (9.75%) |
| **Total** | 123 | | 191 | |